Gang Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gang Cheng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Dapeng Zhang
The Affiliated Bozhou Hospital of Anhui Medical University, Bozhou, 236000, China
1 shared publicationHan Zhao
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China
1 shared publication- Jianhua Chang
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
1 shared publication Jinfeng Guo
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China
1 shared publicationJunjie Hang
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China
1 shared publicationJunjie Huang
JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
1 shared publication
Latest Publications
- Open Access
- 6 April 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (5)
Impact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysis
Background: The optimal sequence of administering immune checkpoint inhibitors (ICIs) and chemotherapy in advanced esophageal cancer (EC) and gastric cancer (GC) remains to be established. Understanding how this sequencing affects overall survival (OS) is crucial for optimizing treatment strategies. Methods: This multicenter study enrolled 334 patients diagnosed with advanced EC or GC between January 2018 and October 2024. To reduce confounding biases, propensity score matching (PSM) was applied, resulting in 292 matched patients categorized into two groups, including those receiving ICIs first (IF) and those receiving chemotherapy first (CF). Results: Following PSM, Kaplan–Meier analysis showed that the CF group had a significantly prolonged median OS compared to the IF group (16.80 vs. 14.60 months; p = 0.014). These findings were further corroborated in the unmatched cohort (16.60 vs. 14.60 months; p = 0.012). Multivariable analysis identified ECOG performance status, PD-L1 expression, antibiotic use, and line of ICI treatment as independent prognostic factors, whereas the i mmunochemotherapy administration sequence did not retain independent prognostic significance. Subgroup analysis revealed that among patients receiving first-line immunochemotherapy, those in the CF group had significantly longer OS (16.50 vs. 12.30 months; p = 0.004), with no significant difference observed for those beyond first-line treatment ( p = 0.862). The objective response rate and disease control rate were comparable between the two groups. Conclusions: This study suggests that administering chemotherapy prior to immunotherapy appears to improve OS in patients with advanced EC and GC, particularly when initiated as first-line treatment. These findings highlight the need for further research into biomarkers and personalized treatment strategies to enhance patient outcomes.
- 6 April 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (5)
Open AccessImpact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysis
Background: The optimal sequence of administering immune checkpoint inhibitors (ICIs) and chemotherapy in advanced esophageal cancer (EC) and gastric cancer (GC) remains to be established. Understanding how this sequencing affects overall survival (OS) is crucial for optimizing treatment strategies. Methods: This multicenter study enrolled 334 patients diagnosed with advanced EC or GC between January 2018 and October 2024. To reduce confounding biases, propensity score matching (PSM) was applied, resulting in 292 matched patients categorized into two groups, including those receiving ICIs first (IF) and those receiving chemotherapy first (CF). Results: Following PSM, Kaplan–Meier analysis showed that the CF group had a significantly prolonged median OS compared to the IF group (16.80 vs. 14.60 months; p = 0.014). These findings were further corroborated in the unmatched cohort (16.60 vs. 14.60 months; p = 0.012). Multivariable analysis identified ECOG performance status, PD-L1 expression, antibiotic use, and line of ICI treatment as independent prognostic factors, whereas the i mmunochemotherapy administration sequence did not retain independent prognostic significance. Subgroup analysis revealed that among patients receiving first-line immunochemotherapy, those in the CF group had significantly longer OS (16.50 vs. 12.30 months; p = 0.004), with no significant difference observed for those beyond first-line treatment ( p = 0.862). The objective response rate and disease control rate were comparable between the two groups. Conclusions: This study suggests that administering chemotherapy prior to immunotherapy appears to improve OS in patients with advanced EC and GC, particularly when initiated as first-line treatment. These findings highlight the need for further research into biomarkers and personalized treatment strategies to enhance patient outcomes.